Millipore shares license

Bayer HealthCare has signed a license agreement with Millipore to use technology that could improve the efficiency of its biopharmaceutical production.

Financial terms of the contract were not disclosed. However, the global, non-exclusive agreement will allow Bayer to use Millipore’s ubiquitous chromatin opening element (UCOE) technology to manufacture its biologic drugs.

Andrew Bulpin, vice-president of Millipore’s upstream bioprocessing business, said: ‘This license is another example of how we can help pharmaceutical and biotech companies efficiently manufacture biologic drugs for both commercial use and for use in clinical development.’

According to Millipore, the technology will allow Bayer to generate higher protein yields in its upstream bioprocessing operations and thus more efficiently manufacture recombinant proteins in mammalian cells. Manufacturing drugs such as recombinant proteins involves growing mammalian cells in a bioreactor, which then produce the required protein, and Millipore’s technology is said to be able to efficiently identify the most productive cells.

Register now to continue reading

Thanks for visiting The Engineer. You’ve now reached your monthly limit of news stories. Register for free to unlock unlimited access to all of our news coverage, as well as premium content including opinion, in-depth features and special reports.  

Benefits of registering

  • In-depth insights and coverage of key emerging trends

  • Unrestricted access to special reports throughout the year

  • Daily technology news delivered straight to your inbox